Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study have?
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study has 35 citations in the OpenAlex counts ScholarIQ stores.
When was Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study published?
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study has 2019 year in the ScholarIQ index.
What is the open-access status of Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study?
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study has closed oa status in the ScholarIQ index.
What is the DOI of Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study?
The DOI for Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study is on the source record.
What is the PMID of Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study?
The PMID for Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study is on the source record.
What is the OpenAlex record for Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study?
The OpenAlex for Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study is on the source record.